Trial Profile

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Metastatic or Advanced Solid Tumors (MAST)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; VAXinia (Primary) ; VAXinia (Primary)
Indications Advanced breast cancer; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Liver cancer; Malignant melanoma; Malignant thymoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Skin cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
Focus Adverse reactions; First in man
Acronyms MAST
Sponsors Imugene

06 Mar 2026 Status changed from active, no longer recruiting to discontinued.
05 Jan 2026 Status changed from recruiting to active, no longer recruiting.
08 Jun 2025 Planned End Date changed from 1 Jan 2025 to 1 Nov 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com